|
1
|
Kreidberg JA, Sariola H, Loring JM, Maeda
M, Pelletier J, Housman D and Jaenisch R: WT-1 is required for
early kidney development. Cell. 74:679–691. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pritchard-Jones K, Fleming S, Davidson D,
Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J
and Housman D: The candidate Wilms' tumour gene is involved in
genitourinary development. Nature. 346:194–197. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang L, Han Y, Saiz Suarez F and Minden
MD: A tumor suppressor and oncogene: The WT1 story. Leukemia.
21:868–876. 2007.PubMed/NCBI
|
|
4
|
Nakatsuka S, Oji Y, Horiuchi T, et al:
Immunohistochemical detection of WT1 protein in a variety of cancer
cells. Mod Pathol. 19:804–814. 2006.PubMed/NCBI
|
|
5
|
Morrison AA, Viney RL and Ladomery MR: The
post-transcriptional roles of WT1, a multifunctional zinc-finger
protein. Biochim Biophys Acta. 1785:55–62. 2008.PubMed/NCBI
|
|
6
|
Im HJ, Kong G and Lee H: Expression of
Wilms tumor gene (WT1) in children with acute leukemia. Pediatr
Hematol Oncol. 16:109–118. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki
JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, et al: The
Wilms' tumor gene WT1 is a good marker for diagnosis of disease
progression of myelodysplastic syndromes. Leukemia. 13:393–399.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sugiyama H: Wilms tumor gene (WT1) as a
new marker for the detection of minimal residual disease in
leukemia. Leuk Lymphoma. 30:55–61. 1998.PubMed/NCBI
|
|
9
|
Trka J, Kalinová M, Hrusák O, Zuna J,
Krejcí O, Madzo J, Sedlácek P, Vávra V, Michalová K, Jarosová M, et
al: Real-time quantitative PCR detection of WT1 gene expression in
children with AML: Prognostic significance, correlation with
disease status and residual disease detection by flow cytometry.
Leukemia. 16:1381–1389. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barragan E, Cervera J, Bolufer P,
Ballester S, Martín G, Fernández P, Collado R, Sayas MJ and Sanz
MA: Prognostic implications of Wilms' tumor gene (WT1) expression
in patients with de novo acute myeloid leukemia. Haematologica.
89:926–933. 2004.PubMed/NCBI
|
|
11
|
Haralambieva E, Banham AH, Bastard C,
Delsol G, Gaulard P, Ott G, Pileri S, Fletcher JA and Mason DY:
Detection by the fluorescence in situ hybridization technique of
MYC translocations in paraffin-embedded lymphoma biopsy samples. Br
J Haematol. 121:49–56. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ogawa H, Tamaki H, Ikegame K, Soma T,
Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, et
al: The usefulness of monitoring WT1 gene transcripts for the
prediction and management of relapse following allogeneic stem cell
transplantation in acute type leukemia. Blood. 101:1698–1704. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cilloni D, Gottardi E, De Micheli D, Serra
A, Volpe G, Messa F, Rege-Cambrin G, Guerrasio A, Divona M, Lo Coco
F and Saglio G: Quantitative assessment of WT1 expression by real
time quantitative PCR may be a useful tool for monitoring minimal
residual disease in acute leukemia patients. Leukemia.
16:2115–2121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gu W, Chen Z, Hu S, Shen H, Qiu G and Cao
X: Changes in expression of WT1 isoforms during induced
differentiation of the NB4 cell line. Haematologica. 90:403–405.
2005.PubMed/NCBI
|
|
15
|
Fenaux P, Mufti GJ, Hellstrom-Lindberg E,
Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz
G, List A, et al: Efficacy of azacitidine compared with that of
conventional care regimens in the treatment of higher-risk
myelodysplastic syndromes: A randomised, open-label, phase III
study. Lancet Oncol. 10:223–232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Steensma DP, Baer MR, Slack JL, Buckstein
R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S,
Cullen MT and Kantarjian H: Multicenter study of decitabine
administered daily for 5 days every 4 weeks to adults with
myelodysplastic syndromes: The alternative dosing for outpatient
treatment (ADOPT) trial. J Clin Oncol. 27:3842–3848. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Voso MT, Santini V, Finelli C, et al:
Valproic acid at therapeutic plasma levels may increase
5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Clin Cancer Res. 15:5002–5007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Christman JK: 5-Azacytidine and
5-aza-2′-deoxycytidine as inhibitors of DNA methylation:
Mechanistic studies and their implications for cancer therapy.
Oncogene. 21:5483–5495. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cashen AF, Schiller GJ, O'Donnell MR and
DiPersio JF: Multicenter, phase II study of decitabine for the
first-line treatment of older patients with acute myeloid leukemia.
J Clin Oncol. 28:556–561. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donner A: Leukemia: PHFriends with RAR.
Nat Chem Biol. 9:291. 2013. View Article : Google Scholar
|
|
21
|
Yang J, Ikezoe T, Nishioka C and Yokoyama
A: Over-expression of Mcl-1 impairs the ability of ATRA to induce
growth arrest and differentiation in acute promyelocytic leukemia
cells. Apoptosis. 18:1403–1415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao L, Bellantuono I, Elsässer A, Marley
SB, Gordon MY, Goldman JM and Stauss HJ: Selective elimination of
leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes
specific for WT1. Blood. 95:2198–2203. 2000.PubMed/NCBI
|
|
23
|
Baird PN and Simmons PJ: Expression of the
Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol.
25:312–320. 1997.PubMed/NCBI
|
|
24
|
Zhao Y, Chen ZX, Hu SY, Cen JN and Gu WY:
Study on DNA methylation status of WT1 gene in its promoter region
in hematologic malignancy cell lines. Zhonghua Xue Ye Xue Za Zhi.
26:517–520. 2005.(In Chinese). PubMed/NCBI
|
|
25
|
Fazi F, Travaglini L, Carotti D, Palitti
F, Diverio D, Alcalay M, McNamara S, Miller WH Jr, Lo Coco F,
Pelicci PG and Nervi C: Retinoic acid targets
DNA-methyltransferases and histone deacetylases during APL blast
differentiation in vitro and in vivo. Oncogene. 24:1820–1830. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lubbert M, Rüter BH, Claus R, Schmoor C,
Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker
U, et al: A multicenter phase II trial of decitabine as first-line
treatment for older patients with acute myeloid leukemia judged
unfit for induction chemotherapy. Haematologica. 97:393–401. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiang L, Dong W, Wang R, Wei J, Qiu G, Cen
J, Chen Z, Zheng X, Hu S, Xie X, et al: All trans retinoic acid
enhances the effect of 5 aza 2′ deoxycytidine on p16INK4a
demethylation, and the two drugs synergistically activate retinoic
acid receptor β gene expression in the human erythroleukemia K562
cell line. Oncol Lett. 8:117–122. 2014.PubMed/NCBI
|
|
28
|
Sugiyama H: Wilms' tumor gene WT1: Its
oncogenic function and clinical application. Int J Hematol.
73:177–187. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scharnhorst V, van der Eb AJ and Jochemsen
AG: WT1 proteins: Functions in growth and differentiation. Gene.
273:141–161. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ariyaratana S and Loeb DM: The role of the
Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
Expert Rev Mol Med. 9:1–17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rosenfeld C, Cheever MA and Gaiger A: WT1
in acute leukemia, chronic myelogenous leukemia and myelodysplastic
syndrome: Therapeutic potential of WT1 targeted therapies.
Leukemia. 17:1301–1312. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gu WY, Chen ZX, Cao XS, Hu SY, Zhu J, Wang
ZL, Yan F, Wang W, Cen JN, Shen HL and Qian J: Detection of WT1
expression in bone marrow of acute leukemia patients with real-time
quantitative RT-PCR. Zhonghua Xue Ye Xue Za Zhi. 25:728–731.
2004.(In Chinese). PubMed/NCBI
|
|
33
|
Sekiya M, Adachi M, Hinoda Y, Imai K and
Yachi A: Downregulation of Wilms' tumor gene (wt1) during
myelomonocytic differentiation in HL60 cells. Blood. 83:1876–1882.
1994.PubMed/NCBI
|
|
34
|
Wang L, Chen ZX, Fu JX, Cen JN and Wang W:
Change of WT1 gene expression during induction of differentiation
of NB4 cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 9:128–131.
2001.(In Chinese). PubMed/NCBI
|
|
35
|
Weisser M, Kern W, Rauhut S, Schoch C,
Hiddemann W, Haferlach T and Schnittger S: Prognostic impact of
RT-PCR-based quantification of WT1 gene expression during MRD
monitoring of acute myeloid leukemia. Leukemia. 19:1416–1423. 2005.
View Article : Google Scholar : PubMed/NCBI
|
